NovoCure Ltd. (NVCR) PT Raised to $250 at Northland Capital Markets

April 14, 2021 9:17 AM EDT
Get Alerts NVCR Hot Sheet
Price: $223.69 -0.84%

Rating Summary:
    7 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 5 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Northland Capital Markets analyst Jason Wittes raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $250.00 (from $200.00) while maintaining an Outperform rating.

The analyst commented, "Yesterday NVCR announced that following pre-specified annual review by the independent Data Monitoring Committee (DMC) for the Phase 3 pivotal LUNAR trial (Optune/TTF fields in stage 4 non-small cell lung cancer (NSCLC) following platinum failure) is recommended accelerating the trial. This was based on the length of accrual and the number of events observed in the 210 patients enrolled through February."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change